S&P Futures
4,151.50 +9.75 (+0.24%) Dow Futures
32,855.00 +63.00 (+0.19%) Nasdaq Futures
13,217.50 +34.25 (+0.26%) Russell 2000 Futures
1,946.30 +5.20 (+0.27%) Crude Oil
90.59 -0.17 (-0.19%) Gold
1,786.40 -0.40 (-0.02%)
United Therapeutics Corporation (UTHR)
After hours:
Chart Events
Performance Outlook
| Previous Close | 221.65 |
| Open | 220.44 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 3000 |
| Day's Range | 212.02 - 222.95 |
| 52 Week Range | 158.38 - 245.48 |
| Volume | |
| Avg. Volume | 501,961 |
| Market Cap | 9.956B |
| Beta (5Y Monthly) | 0.53 |
| PE Ratio (TTM) | 16.53 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for UTHR
Related Research
- United Therapeutics CorporationAnalyst Report: United Therapeutics CorporationUnited Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.RatingFair ValueEconomic Moat22 days agoMorningstar
- Business Wire
United Therapeutics Corporation Reports Second Quarter 2022 Financial Results
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., August 03, 2022--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended June 30, 2022. Total revenues in the second quarter of 2022 grew 5% year-over-year to $466.9 million, compared to $446.5 million in the second quarter of 2021.
- Business Wire
United Therapeutics Corporation to Report Second Quarter 2022 Financial Results Before the Market Opens on Wednesday, August 3, 2022
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., July 27, 2022--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its second quarter 2022 financial results before the market opens on Wednesday, August 3, 2022.
- Business Wire
United Therapeutics Provides an Update on Its Organ Printing Programs
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. & ROCK HILL, S.C., June 06, 2022--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that in partnership with 3D Systems Corporation (NYSE: DDD) it has produced the world’s most complex 3D-printed object – a human lung scaffold – and demonstrated it at the LIFE ITSELF Conference that occurred May 31 to June 3, 2022 in San Diego. The event was organized and hosted by Dr. Sanjay Gupta and Marc Hodosh and w
